Paraoxonase and arylesterase activities in coronary artery disease

M Gur1, M Aslan, A Yildiz

  • 1Harran University, Sanliurfa, Turkey. drmugur@yahoo.com

Insights

Reduced paraoxonase activity and thiol levels are linked to coronary artery disease (CAD) severity. Lower enzyme activity and -SH levels may contribute to atherosclerosis progression in CAD patients.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Oxidative Stress Research

Background:

  • Paraoxonase-1 (PON1) enzyme activities are inversely correlated with cardiovascular diseases.
  • Investigating PON1 activities and oxidative/anti-oxidative status in coronary artery disease (CAD) is crucial.
  • The study aims to correlate these markers with the extent of CAD.

Purpose of the Study:

  • To investigate paraoxonase and arylesterase activities in patients with coronary artery disease.
  • To evaluate the oxidative and anti-oxidative status in relation to CAD.
  • To determine the correlation between these markers and the severity of CAD.

Main Methods:

  • Included 193 CAD patients, 83 normal coronary angiogram (NCAD) patients, and 55 healthy controls.
  • Measured serum paraoxonase, arylesterase activities, lipid hydroperoxide (LOOH), total anti-oxidant status (TAS), and free sulfhydryl groups (-SH).
  • Calculated Gensini score and analyzed lipid parameters to assess CAD extent and patient characteristics.

Main Results:

  • CAD patients exhibited lower paraoxonase, arylesterase activities, TAS, and -SH levels compared to NCAD and control groups.
  • Serum LOOH levels were significantly higher in the CAD group.
  • The 3-vessel disease group showed the most pronounced alterations in these markers, with paraoxonase activity and -SH levels independently correlating with the Gensini score.

Conclusions:

  • Paraoxonase activity and -SH levels are independently associated with CAD presence and severity.
  • Diminished paraoxonase activity and -SH levels may contribute to the progression of coronary atherosclerosis.
  • These findings highlight potential biomarkers for assessing CAD risk and extent.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...